Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Shanghai Haohai Biological Technology Co., Ltd.
  6. Summary
    6826   CNE100001W69

SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.

(6826)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
56 53.95 53.05 53.5 51.55 Last
856500 329000 198300 390100 169300 Volume
+0.90% -3.66% -1.67% +0.85% -3.64% Change
Estimated financial data (e)
Sales 2021 1 889 M 298 M 298 M
Net income 2021 474 M 74,8 M 74,8 M
Net cash position 2021 3 276 M 517 M 517 M
P/E ratio 2021 15,4x
Yield 2021 1,78%
Sales 2022 2 308 M 364 M 364 M
Net income 2022 600 M 94,7 M 94,7 M
Net cash position 2022 3 488 M 550 M 550 M
P/E ratio 2022 12,5x
Yield 2022 2,11%
Capitalization 16 468 M 2 598 M 2 598 M
EV / Sales 2021 6,98x
EV / Sales 2022 5,62x
Nbr of Employees 1 374
Free-Float 38,5%
More Financials
Company
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical... 
More about the company
Ratings of Shanghai Haohai Biological Technology Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
2021Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 3,..
CI
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : 688366) added to Shanghai Stock Exchange Health Car..
CI
2021Haohai Biological Buys 51% Stake in Contact Lens Maker for $11 Million
MT
2021Shanghai Haohai Biological Technology's Q3 Profit Drops 6.6% as R&D Expenses Rise
MT
2021Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Nine M..
CI
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Projects Up to 193% Growth in January-September Pro..
MT
2021Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for th..
CI
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : 688366) added to S&P Global BMI Index
CI
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Haohai Biological Technology's H1 Profit Leaps 739%..
MT
2021Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan..
CI
2021Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Half Y..
CI
2021ARCSCAN, INC. : Signs Definitive Agreement for $11.15 Million Preferred Series B Investmen..
PR
2021ArcScan, Inc. announced that it expects to receive $11.15 million in funding from Shang..
CI
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Expects Huge Jump in First-Half Profit
MT
2021Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Earning..
CI
More news
News in other languages on SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : 6826) lance un plan de rachat d'actions portant sur..
2021Haohai Biological achète 51 % des parts d'un fabricant de lentilles de contact pour 11 ..
2021Le bénéfice du troisième trimestre de Shanghai Haohai Biological Technology chute de 6,..
2021Shanghai Haohai Biological Technology prévoit une croissance de 193 % de son bénéfice d..
2021Shanghai Haohai Biological Technology Co., Ltd. fournit des prévisions de bénéfices pou..
More news
Chart SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Duration : Period :
Shanghai Haohai Biological Technology Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 41,96 CNY
Average target price 92,92 CNY
Spread / Average Target 121%
EPS Revisions
Managers and Directors
Jian Ying Wu General Manager & Director
Min Jie Tang Chief Financial Officer & Executive Director
Yong Tai Hou Chairman
Yuan Zhong Liu Chairman-Supervisory Board
Chang Zheng Wei Deputy Manager-Research & Development
Sector and Competitors